ResMed Inc. vs SoFi Technologies Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while SoFi Technologies Inc trades at $15.74 (market cap $20.16B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and SoFi Technologies Inc for 60 Days on average.
| RMD | SOFI | |
|---|---|---|
Market Cap | $31.89B | $20.16B |
Volume | 618,314 | 49,646,331 |
Sector | Health | Financials |
52-Week High | $277.88 | $32.21 |
52-Week Low | $182.82 | $15.15 |
Typical Hold Time | 51 Days | 60 Days |
Enterprise Value | $31.24B | $20.30B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
SOFI Technologies stock trades at $15.66, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue has grown from $1.6B in 2022 to $3.6B in 2025, though net income margins have fluctuated. Analyst consensus is a Buy with a $21.58 price target, but technical indicators suggest near-term pressure.
The outlook for SOFI is mixed: strong fundamentals and growth potential are offset by technical weakness and competitive risks. Investment opportunity lies in its revenue trajectory and market position, but investors face risks from execution challenges and interest rate sensitivity. The stock's current valuation metrics indicate premium pricing relative to peers, requiring careful monitoring of upcoming earnings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →